Back to Agenda
Addressing the Elephant in the Room: A Hard Look at Metrics, Legal, Payers, and Other Leading Obstacles Facing the Sustainability of Patient Engagement
Session Chair(s)
Katherine Capperella
VP, Global Patient Engagement Leader, Johnson & Johnson, United States
As the industry continues to evolve and incorporate the patient’s voice into drug development - ultimately toward the stage of regular and continuous integrative collaboration - this session will discuss how it’s essential to openly assess and discuss common topics and challenges that may impact the long-term sustainability of patient engagement.
Learning Objective : Identify the needs of private payers when defining the value of healthcare treatments and interventions; Describe the legal, regulatory, and compliance considerations that biopharmaceutical companies must address to develop and execute sustainable, ethical and compliant patient engagement initiatives; Evaluate methodologies that biopharmaceutical companies are using to measure internal changes related to regularly, efficiently, and successfully implementing patient-centric solutions.
Speaker(s)
Rebecca Vermeulen, RPH
Vice President, Global Patient Networks | PD Medical Affairs, Genentech, A Member of the Roche Group, United States
Jayne C. Gershkowitz
Chief Patient Advocate, Amicus Therapeutics, United States
Patrik Florencio, JD
Senior Vice President, Global Chief Compliance and Risk Officer, Amicus Therapeutics, United States
Samuel R. Nussbaum, MD
Strategic Consultant, EBG Advisors, Inc., United States
Have an account?